Detecting treatment-resistant mutations associated with leukemia relapse is key to pre-emptive intervention
Luke Turner |
Acute myeloid leukemia (AML) is the most common type of blood cancer in adults. Starting suddenly and progressing rapidly, even those who achieve remission can’t breathe easy; as many as one-third of patients who receive chemotherapy and a bone marrow transplant will relapse within three to six months. Unfortunately, transplantation is the only curative treatment for AML, so patients who relapse are left with few options.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine